Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106378 | 1.00 | BDKRB1 (0.36) | BDKRB1KCNH2MCHR1CHEK1KMT2A | |
| SCHEMBL14138919 | 0.90 | PRMT5 (0.35) | BDKRB1MCHR1KMT2APRMT5WDR77 | |
| SCHEMBL5097165 | 0.88 | GRM2 (0.34) | BDKRB1KCNH2MCHR1KMT2APRMT5 | |
| SCHEMBL5007692 | 0.85 | BDKRB1 (0.37) | BDKRB1KCNH2MCHR1PRMT5WDR77 | |
| SCHEMBL4997337 | 0.84 | BDKRB1 (0.34) | BDKRB1MCHR1KMT2APRMT5WDR77 | |
| SCHEMBL5001845 | 0.84 | BDKRB1 (0.41) | BDKRB1MCHR1KMT2AMEN1 | |
| SCHEMBL4997334 | 0.84 | BDKRB1 (0.34) | BDKRB1MCHR1KMT2APRMT5WDR77 | |
| SCHEMBL5001844 | 0.84 | BDKRB1 (0.41) | BDKRB1MCHR1KMT2AMEN1 | |
| SCHEMBL5134077 | 0.84 | BDKRB1 (0.34) | BDKRB1MCHR1KMT2APRMT5WDR77 | |
| SCHEMBL14029677 | 0.82 | MDM4 (0.38) | BDKRB1MCHR1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | BDKRB1, BDKRB2, EDNRB | BDKRB1 1/4885KCNH2 262/4885MCHR1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.